The CDC says more than 200 diagnosed in fungal meningitis outbreak. If it gets widespread the FDA will regret not approving Neuprex. Xoma failed to get approval in the face of reducing 75% of amputations.Failed to improved the death rate because patients didn't get the fully perscribed dose in time. The failure of Neuprex came in the trial design. NOT in the drugs usefulness.
even if it woulda, coulda, shoulda:
apparently many years ago:
"DEERFIELD, Ill. and BERKELEY, Calif., Jan. 24 /PRNewswire/ -- Baxter
Healthcare Corporation and XOMA Ltd. (Nasdaq: XOMA) announced today an
agreement in which Baxter's Hyland Immuno division has acquired the worldwide
rights to XOMA's NEUPREX(R) (rBPI21) for treatment of meningococcemia and all
future anti-bacterial and anti-endotoxin indications. Meningococcemia is a
deadly systemic bacterial infection caused by a species of bacteria that can
also cause meningitis.
The terms of the agreement call for XOMA to receive upfront and other
payments related to the meningococcemia indication aggregating $35 million.
Additional payments will be made upon the achievement of development
milestones for future indications. Baxter will pay all future clinical
development costs as well as royalties appropriate for a late-stage product.
Under a separate supply agreement, a XOMA affiliate will manufacture the
product for Baxter at its Berkeley facilities; Baxter has future rights to
manufacture the product.
XOMA's meningococcemia Phase III trial tested the NEUPREX(R) product in
nearly 400 patients. The U.S. and U.K. study was the largest clinical trial
ever conducted in children and teenagers with this serious and debilitating
bacterial infection. The U.S. Food and Drug Administration (FDA) has granted
the product Subpart E designation and Orphan Drug status for meningococcemia.
"The science behind NEUPREX(R), and the BPI platform for product
development, are complementary to our recombinant and vaccines businesses,"
said Thomas Glanzmann, president, Hyland Immuno. "It serves as an excellent
illustration of the strategic growth underway at Hyland Immuno as we diversify
our biotechnology portfolio."
"We're pleased to have Baxter as our ally," said Jack Castello, chairman,
president and CEO of XOMA. "They have excellent worldwide marketing and sales
capabilities, particularly in the critical care and emergency hospital market.
With Baxter's involvement, we believe we can maximize the value of NEUPREX(R)
by aiming not only for meningococcemia but also for a wide variety of other
"I am delighted about this relationship with XOMA," said Norbert Riedel,
Ph.D., president of Hyland Immuno's Recombinant business. "NEUPREX(R)
addresses an unmet medical need for a critically-ill patient population, and
allows Baxter Hyland Immuno the opportunity to bring this product as quickly
as possible to patients and their families who so desperately need it."
Outbreaks of meningococcemia have become more frequent in recent years.
The disease is characterized by very rapid onset of life-threatening symptoms
with high mortality. In survivors, gangrene followed by amputation and/or
central nervous system damage are common morbidities. Although the bacteria
which causes meningococcemia are generally controlled by first-line
antibiotics, there is no current treatment for the toxic inflammatory cascade
triggered by bacterial endotoxin that can lead to organ failure, shock and
Baxter Healthcare Corporation is the principal domestic operating
subsidiary of Baxter International Inc. (NYSE: BAX). Baxter is a global
leader in providing critical therapies for life-threatening conditions,
focusing on blood therapies, medication delivery, renal therapy, and
cardiovascular medicine. Baxter offers products and services that are used by
health-care providers and their patients in 112 countries. The Hyland Immuno
division of Baxter develops and produces therapeutic proteins from plasma and
through recombinant methods to treat hemophilia, immune deficiencies and other
blood-related disorders. Hyland Immuno's portfolio of therapies includes
coagulation factors, immune globulins, albumin, wound management products, and
XOMA develops and manufactures biopharmaceuticals at facilities located in
Berkeley and Santa Monica, California. Medical targets include bacterial and
fungal infections, infectious complications, immunologic and inflammatory
disorders. The Company's primary drug development platform is BPI
(bactericidal/permeability-increasing protein), a human protein found in white
blood cells (neutrophils) and one of the body's natural defenses against
infections. BPI was discovered by Peter Elsbach, MD, and Jerrold Weiss, PhD,
at New York University School of Medicine. This news release contains forward looking statements that involve risks
and uncertainties, including those related to timing or results of pending or
future clinical trials, changes in the status of collaborative relationships,
actions by the U.S. Food and Drug Administration or the U.S. Patent and
Trademark Office, technological advances in the medical field, product demand
and market acceptance, the effect of economic conditions, the impact of
competitive products and pricing, foreign currency exchange rates and other
risks detailed in the companies' filings with the Securities and Exchange
Commission. These forward looking statements are based on estimates and
assumptions made by management of the companies and are believed to be
reasonable, though are inherently uncertain and difficult to predict. Actual
results or experience could differ materially from the forward-looking
SOURCE Baxter Healthcare Corporation"
Why cut and paste an article that showed Xoma partnering with Baxter a dozen years ago and then fail to mention that Xoma re-aquired Neuprex after where they now own 100% of it and all associated active patents? A little misleading don't you think?
that was a long time ago- it failed the meninococcemia study, a traumatic shock study as i recall, and even failed to help acne-( I wonder if 052 can?) I cant go back far enough ( in my senile memory) to remember that CEO- certainly befopr Engle- I would guess that to be at least 10 yrs old just opinion